Cvijic Christine Mikail 4

4 · Neurogene Inc. · Filed Mar 3, 2026

AI-generated summary of this filing

Updated Mar 3, 2026

Neurogene (NGNE) President & CFO Christine Cvijic Sells 4,800 Shares

What Happened

Christine Mikail Cvijic, President and Chief Financial Officer of Neurogene Inc., sold 4,800 shares on 2026-02-27 in an open-market sale. The reported weighted-average price was $25.11 per share (range $25.00–$25.325), for total proceeds of $120,526. This was a sale (routine disposition) executed under a pre-established 10b5-1 trading plan.

Key Details

Transaction date and price(s): 2026-02-27; weighted-average price $25.11; individual trade prices ranged $25.00–$25.325.
Shares sold: 4,800; Transaction code: S (sale).
Ownership after transaction: The Form 4 does not state a single total of shares beneficially owned after this sale. It discloses remaining unvested restricted stock units totaling 63,569 (21,269 + 20,300 + 22,000) with specified future vesting dates, and notes 19,200 shares are held jointly by Ms. Cvijic and her spouse, David Cvijic.
Notable footnotes: (1) Sale was effected pursuant to a 10b5-1 plan adopted Aug 18, 2025; shares sold were held jointly with spouse. (2) Price reported is a weighted average; the filer can provide a breakdown of number of shares sold at each price upon request.
Filing timeliness: Transaction reported on Form 4 filed 2026-03-03 for a 2026-02-27 trade; this filing date is within the typical two-business-day reporting window and is treated as timely.

Context

This was an open-market sale under a 10b5-1 plan, which is a pre-arranged trading program that allows insiders to sell shares on a set schedule and is generally considered a routine disposition rather than a spontaneous signal about company prospects. No options were exercised and no gifts were reported in this filing.

Form 4

Period: 2026-02-27

President and CFO

Transactions

Footnotes (3)

[F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.

Signature

/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic|2026-03-03

1 file